232 related articles for article (PubMed ID: 29588131)
1. Protective Effects of Micronized Purified Flavonoid Fraction (MPFF) on a Novel Experimental Model of Chronic Venous Hypertension.
das Graças C de Souza M; Cyrino FZ; de Carvalho JJ; Blanc-Guillemaud V; Bouskela E
Eur J Vasc Endovasc Surg; 2018 May; 55(5):694-702. PubMed ID: 29588131
[TBL] [Abstract][Full Text] [Related]
2. Different flavonoids present in the micronized purified flavonoid fraction (Daflon 500 mg) contribute to its anti-hyperpermeability effect in the hamster cheek pouch microcirculation.
Paysant J; Sansilvestri-Morel P; Bouskela E; Verbeuren TJ
Int Angiol; 2008 Feb; 27(1):81-5. PubMed ID: 18277344
[TBL] [Abstract][Full Text] [Related]
3. Beneficial effects of the micronized purified flavonoid fraction (MPFF, Daflon® 500 mg) on microvascular damage elicited by sclerotherapy.
de Souza Md; Cyrino FZ; Mayall MR; Virgini-Magalhães CE; Sicuro FL; de Carvalho JJ; Verbeuren TJ; Bouskela E
Phlebology; 2016 Feb; 31(1):50-6. PubMed ID: 25514922
[TBL] [Abstract][Full Text] [Related]
4. Time course of microvalve pathophysiology in high pressure low flow model of venous insufficiency and the role of micronized purified flavonoid fraction.
Cyrino FZ; Blanc-Guillemaud V; Bouskela E
Int Angiol; 2021 Oct; 40(5):388-394. PubMed ID: 34282857
[TBL] [Abstract][Full Text] [Related]
5. Effects of oral administration of purified micronized flavonoid fraction on increased microvascular permeability induced by various agents and on ischemia/reperfusion in the hamster cheek pouch.
Bouskela E; Donyo KA
Angiology; 1997 May; 48(5):391-9. PubMed ID: 9158383
[TBL] [Abstract][Full Text] [Related]
6. Micronization enhances the protective effect of purified flavonoid fraction against postischaemic microvascular injury in the hamster cheek pouch.
Cyrino FZ; Bottino DA; Lerond L; Bouskela E
Clin Exp Pharmacol Physiol; 2004 Mar; 31(3):159-62. PubMed ID: 15008958
[TBL] [Abstract][Full Text] [Related]
7. Microvascular reactivity after ischemia/reperfusion in the hamster cheek pouch: beneficial effects of different oral doses of S-5682 (Daflon 500 mg).
Bouskela E; Cyrino FZ; Lerond L
Angiology; 1997 Jan; 48(1):33-7. PubMed ID: 8995341
[TBL] [Abstract][Full Text] [Related]
8. [Therapeutic potential of micronized purified flavonoid fraction (MPFF) of diosmin and hesperidin in treatment chronic venous disorder].
Hnátek L
Vnitr Lek; 2015 Sep; 61(9):807-14. PubMed ID: 26465280
[TBL] [Abstract][Full Text] [Related]
9. Diosmin/hesperidin: a cooperating tandem, or is diosmin crucial and hesperidin an inactive ingredient only?
Karetová D; Suchopár J; Bultas J
Vnitr Lek; 2020; 66(2):97-103. PubMed ID: 32942884
[TBL] [Abstract][Full Text] [Related]
10. Effects of oral administration of purified micronized flavonoid fraction on increased microvascular permeability induced by various agents and on ischemia/reperfusion in diabetic hamsters.
Bouskela E; Donyo KA
Int J Microcirc Clin Exp; 1995; 15(6):293-300. PubMed ID: 8721438
[TBL] [Abstract][Full Text] [Related]
11. Pharmacologic aspects of a phlebotropic drug in CVI-associated edema.
Ramelet AA
Angiology; 2000 Jan; 51(1):19-23. PubMed ID: 10667639
[TBL] [Abstract][Full Text] [Related]
12. Micronised purified flavonoid fraction: a review of its use in chronic venous insufficiency, venous ulcers and haemorrhoids.
Lyseng-Williamson KA; Perry CM
Drugs; 2003; 63(1):71-100. PubMed ID: 12487623
[TBL] [Abstract][Full Text] [Related]
13. Is There a Difference in the Clinical Efficacy of Diosmin and Micronized Purified Flavonoid Fraction for the Treatment of Chronic Venous Disorders? Review of Available Evidence.
Cazaubon M; Benigni JP; Steinbruch M; Jabbour V; Gouhier-Kodas C
Vasc Health Risk Manag; 2021; 17():591-600. PubMed ID: 34556990
[TBL] [Abstract][Full Text] [Related]
14. The inflammatory reaction during venous hypertension in the rat.
Takase S; Lerond L; Bergan JJ; Schmid-Schönbein GW
Microcirculation; 2000 Feb; 7(1):41-52. PubMed ID: 10708336
[TBL] [Abstract][Full Text] [Related]
15. Effects of Daflon 500 mg on increased microvascular permeability in normal hamsters.
Bouskela E; Donyo KA; Verbeuren TJ
Int J Microcirc Clin Exp; 1995; 15 Suppl 1():22-6. PubMed ID: 8748885
[TBL] [Abstract][Full Text] [Related]
16. The effects of doxycycline and micronized purified flavonoid fraction on human vein wall remodeling are not hypoxia-inducible factor pathway-dependent.
Lim CS; Kiriakidis S; Paleolog EM; Davies AH
J Vasc Surg; 2012 Oct; 56(4):1069-77. PubMed ID: 22677007
[TBL] [Abstract][Full Text] [Related]
17. Recommendations for the medical management of chronic venous disease: The role of Micronized Purified Flavanoid Fraction (MPFF).
Bush R; Comerota A; Meissner M; Raffetto JD; Hahn SR; Freeman K
Phlebology; 2017 Apr; 32(1_suppl):3-19. PubMed ID: 28211296
[TBL] [Abstract][Full Text] [Related]
18. Administration of Micronized Purified Flavonoid Fraction During Sclerotherapy of Reticular Veins and Telangiectasias: Results of the National, Multicenter, Observational Program VEIN ACT PROLONGED-C1.
Bogachev VY; Boldin BV; Turkin PY
Adv Ther; 2018 Jul; 35(7):1001-1008. PubMed ID: 29949043
[TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy of micronized purified flavonoid fraction: an overview.
Struckmann JR
J Vasc Res; 1999; 36 Suppl 1():37-41. PubMed ID: 10474049
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms in experimental venous valve failure and their modification by Daflon 500 mg.
Pascarella L; Lulic D; Penn AH; Alsaigh T; Lee J; Shin H; Kapur V; Bergan JJ; Schmid-Schönbein GW
Eur J Vasc Endovasc Surg; 2008 Jan; 35(1):102-10. PubMed ID: 17890112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
